Cargando…
Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients
Objective: To examine the incidence rates and association between dose-intensity, stratified by exposure duration, of bisphosphonates and the risk of osteonecrosis of the jaw among Korean osteoporotic patients older than 50 years. Study Design and Setting: Using the population-based National Health...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062614/ https://www.ncbi.nlm.nih.gov/pubmed/30079024 http://dx.doi.org/10.3389/fphar.2018.00796 |
_version_ | 1783342407597686784 |
---|---|
author | Jung, Sung-mok Han, Sujeong Kwon, Hye-Young |
author_facet | Jung, Sung-mok Han, Sujeong Kwon, Hye-Young |
author_sort | Jung, Sung-mok |
collection | PubMed |
description | Objective: To examine the incidence rates and association between dose-intensity, stratified by exposure duration, of bisphosphonates and the risk of osteonecrosis of the jaw among Korean osteoporotic patients older than 50 years. Study Design and Setting: Using the population-based National Health Insurance Claims Data of Korea from January 1, 2006, through December 3, 2012, 13,730 new bisphosphonate users as of 2006 were identified. Truncated age-standardized incidence rate estimation and multivariate logistic regression analyses were conducted. Results: In this retrospective cohort study, increasing age-standardized incidence rates of ONJ attributed to bisphosphonate exposure were observed for individuals with less than 1 year, 1–2 years, over 2 years of defined daily dose (DDD) of bisphosphonate exposure (13.85, 16.19, and 38.20, respectively), using a truncated 2000 United States Standard Population. Also, over 2 years of bisphosphonate DDDs was associated with an increased risk of developing of ONJ with an adjusted odds ratio of 1.51 (95% confidence interval: 1.31–1.75), compared to individuals with less than 1 year of bisphosphonate exposure. Conclusion: Our data provided the evidence to support the association between risk of ONJ and duration of bisphosphonate exposure used in the treatment or prevention of osteoporosis. |
format | Online Article Text |
id | pubmed-6062614 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-60626142018-08-03 Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients Jung, Sung-mok Han, Sujeong Kwon, Hye-Young Front Pharmacol Pharmacology Objective: To examine the incidence rates and association between dose-intensity, stratified by exposure duration, of bisphosphonates and the risk of osteonecrosis of the jaw among Korean osteoporotic patients older than 50 years. Study Design and Setting: Using the population-based National Health Insurance Claims Data of Korea from January 1, 2006, through December 3, 2012, 13,730 new bisphosphonate users as of 2006 were identified. Truncated age-standardized incidence rate estimation and multivariate logistic regression analyses were conducted. Results: In this retrospective cohort study, increasing age-standardized incidence rates of ONJ attributed to bisphosphonate exposure were observed for individuals with less than 1 year, 1–2 years, over 2 years of defined daily dose (DDD) of bisphosphonate exposure (13.85, 16.19, and 38.20, respectively), using a truncated 2000 United States Standard Population. Also, over 2 years of bisphosphonate DDDs was associated with an increased risk of developing of ONJ with an adjusted odds ratio of 1.51 (95% confidence interval: 1.31–1.75), compared to individuals with less than 1 year of bisphosphonate exposure. Conclusion: Our data provided the evidence to support the association between risk of ONJ and duration of bisphosphonate exposure used in the treatment or prevention of osteoporosis. Frontiers Media S.A. 2018-07-20 /pmc/articles/PMC6062614/ /pubmed/30079024 http://dx.doi.org/10.3389/fphar.2018.00796 Text en Copyright © 2018 Jung, Han and Kwon. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Jung, Sung-mok Han, Sujeong Kwon, Hye-Young Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients |
title | Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients |
title_full | Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients |
title_fullStr | Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients |
title_full_unstemmed | Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients |
title_short | Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients |
title_sort | dose-intensity of bisphosphonates and the risk of osteonecrosis of the jaw in osteoporosis patients |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062614/ https://www.ncbi.nlm.nih.gov/pubmed/30079024 http://dx.doi.org/10.3389/fphar.2018.00796 |
work_keys_str_mv | AT jungsungmok doseintensityofbisphosphonatesandtheriskofosteonecrosisofthejawinosteoporosispatients AT hansujeong doseintensityofbisphosphonatesandtheriskofosteonecrosisofthejawinosteoporosispatients AT kwonhyeyoung doseintensityofbisphosphonatesandtheriskofosteonecrosisofthejawinosteoporosispatients |